Potential of ramucirumab in treating hepatocellular carcinoma patients with elevated baseline alpha-fetoprotein.

J Hepatocell Carcinoma · 2018 · PMC6219272 · PMID 30464931

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

borderline significantno p-value reported

Surprisingly, in the BRISK-FL trial comparing brivanib, a dual inhibitor of FGF and VEGF receptors, to placebo, in second-line postsorafenib, the effi-cacy of brivanib was borderline significant for patients with AFP levels less than 200 ng/mL!

also in 11,409 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.